JP2020502259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502259A5 JP2020502259A5 JP2019545897A JP2019545897A JP2020502259A5 JP 2020502259 A5 JP2020502259 A5 JP 2020502259A5 JP 2019545897 A JP2019545897 A JP 2019545897A JP 2019545897 A JP2019545897 A JP 2019545897A JP 2020502259 A5 JP2020502259 A5 JP 2020502259A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- alkyl
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229940080328 Arginase inhibitor Drugs 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 238000009169 immunotherapy Methods 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 102000004452 Arginase Human genes 0.000 claims 1
- 108700024123 Arginases Proteins 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 210000004404 adrenal cortex Anatomy 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 150000001638 boron Chemical class 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419250P | 2016-11-08 | 2016-11-08 | |
| US62/419,250 | 2016-11-08 | ||
| US201762559931P | 2017-09-18 | 2017-09-18 | |
| US62/559,931 | 2017-09-18 | ||
| PCT/US2017/060636 WO2018089490A1 (en) | 2016-11-08 | 2017-11-08 | Arginase inhibitor combination therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020502259A JP2020502259A (ja) | 2020-01-23 |
| JP2020502259A5 true JP2020502259A5 (cg-RX-API-DMAC7.html) | 2020-12-03 |
Family
ID=60409467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545897A Pending JP2020502259A (ja) | 2016-11-08 | 2017-11-08 | アルギナーゼ阻害剤併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11291674B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3538111B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020502259A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190104521A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110352063A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017356942A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3042878A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL266534A (cg-RX-API-DMAC7.html) |
| MA (1) | MA46793A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019005402A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12019501010A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201828959A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018089490A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| EP3743510A1 (en) * | 2018-01-28 | 2020-12-02 | Universite De Geneve | Arginase suppression for cancer treatment |
| SG11202007739XA (en) | 2018-02-17 | 2020-09-29 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| WO2019173188A1 (en) | 2018-03-05 | 2019-09-12 | Arcus Biosciences, Inc. | Arginase inhibitors |
| US12215116B2 (en) | 2018-03-13 | 2025-02-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| AU2019246728A1 (en) | 2018-03-29 | 2020-08-27 | Oncoarendi Therapeutics S.A. | Dipeptide piperidine derivatives |
| CA3098471C (en) * | 2018-05-22 | 2023-04-18 | Nantkwest, Inc. | Optimization of nk-92 cell growth using poloxamer |
| MA53427B1 (fr) * | 2018-08-22 | 2024-06-28 | Astrazeneca Ab | Inhibiteurs de l'arginase et leurs méthodes d'utilisation |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3880685B1 (en) * | 2018-11-16 | 2025-06-18 | Arcus Biosciences, Inc. | Inhibitors of arg1 and/or arg2 |
| CN113614095B (zh) * | 2019-02-06 | 2024-08-23 | 广东新契生物医药科技有限公司 | 作为精氨酸酶抑制剂的烷基硼酸类化合物 |
| WO2021090146A1 (en) * | 2019-11-04 | 2021-05-14 | Astrazeneca Ab | Combination therapy for treating cancer |
| CN110734456A (zh) * | 2019-11-06 | 2020-01-31 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和医药上的应用 |
| CN111138358B (zh) * | 2019-12-17 | 2023-04-18 | 中国药科大学 | Usp8抑制剂及其制备方法与应用 |
| EP4251202A4 (en) * | 2020-11-30 | 2025-04-09 | Merck Sharp & Dohme LLC | ARGINASE-1 BINDING AGENT FOR INHIBITING ARGINASE-1 ACTIVITY |
| WO2022115350A1 (en) * | 2020-11-30 | 2022-06-02 | Merck Sharp & Dohme Corp. | Arginase 1 binders for inhibiting arginase 1 activity |
| JP2024507199A (ja) * | 2021-02-20 | 2024-02-16 | カイト ファーマ インコーポレイテッド | 免疫療法を選択するための遺伝子マーカー |
| US12653889B2 (en) * | 2021-04-06 | 2026-06-16 | Smt Bio Co., Ltd. | Composition for preventing or treating extrahepatic bile duct cancer |
| JP7720412B2 (ja) * | 2021-05-13 | 2025-08-07 | ベンタナ メディカル システムズ， インコーポレイテッド | 組織固定時間のリアルタイム予測 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| DE69818675T2 (de) | 1997-07-29 | 2004-07-29 | Alcon Laboratories, Inc., Fort Worth | Galaktomannanpolymere und borat enthaltende augenarzneimittel |
| AU9797998A (en) | 1997-10-10 | 1999-05-03 | Trustees Of The University Of Pennsylvania, The | Compositions and methods for inhibiting arginase activity |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| WO2002004465A1 (en) | 2000-07-06 | 2002-01-17 | Fal Diagnostics | Methods and kits for the detection of arginine compounds |
| CA2431080A1 (en) | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| EP1654002B2 (en) | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| EP1915143A4 (en) | 2005-07-01 | 2009-11-11 | Univ Johns Hopkins | ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE |
| WO2010085797A2 (en) | 2009-01-26 | 2010-07-29 | The Trustees Of University Of Pennsylvania | Arginase inhibitors and methods of use |
| EP2560978B1 (en) | 2010-04-22 | 2019-01-30 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| EP3034509B1 (en) * | 2010-10-26 | 2020-04-22 | Mars, Incorporated | Arginase inhibitors as therapeutics |
| RU2019121905A (ru) | 2010-12-31 | 2019-09-03 | Астразенека Юкей Лимитед | Ингибиторы аргиназы и способы их применения |
| CA2852685C (en) | 2011-10-19 | 2019-02-26 | Mars, Incorporated | Inhibitors of arginase and their therapeutic application |
| KR20140077963A (ko) | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
| CN104540836B (zh) | 2012-04-18 | 2016-11-09 | 马尔斯公司 | 作为精氨酸酶抑制剂的环约束类似物 |
| WO2015061752A1 (en) | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
| CN105879030A (zh) | 2014-09-30 | 2016-08-24 | 复旦大学 | 治疗肿瘤的增效药物复合物及其制备方法 |
| KR20170129896A (ko) | 2015-03-20 | 2017-11-27 | 새미 오유 오피요 | 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도 |
| AU2016281620B2 (en) | 2015-06-23 | 2021-07-22 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| DK3368541T3 (da) | 2015-10-30 | 2020-06-29 | Calithera Biosciences Inc | Sammensætninger og metoder til inhibiering af arginaseaktivitet |
-
2017
- 2017-11-08 US US15/807,357 patent/US11291674B2/en active Active
- 2017-11-08 EP EP17801266.2A patent/EP3538111B1/en active Active
- 2017-11-08 CA CA3042878A patent/CA3042878A1/en not_active Abandoned
- 2017-11-08 MX MX2019005402A patent/MX2019005402A/es unknown
- 2017-11-08 AU AU2017356942A patent/AU2017356942A1/en not_active Abandoned
- 2017-11-08 JP JP2019545897A patent/JP2020502259A/ja active Pending
- 2017-11-08 TW TW106138689A patent/TW201828959A/zh unknown
- 2017-11-08 KR KR1020197016533A patent/KR20190104521A/ko not_active Withdrawn
- 2017-11-08 MA MA046793A patent/MA46793A/fr unknown
- 2017-11-08 WO PCT/US2017/060636 patent/WO2018089490A1/en not_active Ceased
- 2017-11-08 CN CN201780076069.4A patent/CN110352063A/zh active Pending
-
2019
- 2019-05-07 PH PH12019501010A patent/PH12019501010A1/en unknown
- 2019-05-08 IL IL266534A patent/IL266534A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6956967B2 (ja) | Ｗｔ１抗原ペプチドおよび免疫調節剤の併用 | |
| JP2021185146A (ja) | アルギナーゼ活性を阻害するための組成物および方法 | |
| JP2018521135A5 (cg-RX-API-DMAC7.html) | ||
| JP2018507197A5 (cg-RX-API-DMAC7.html) | ||
| EP4327877A3 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| JP6240083B2 (ja) | 樹状細胞癌ワクチンのための小分子エンハンサー | |
| US20240065987A1 (en) | Anti-cancer activity of adamantane derivatives | |
| WO2016104657A1 (ja) | 癌治療剤 | |
| TWI829329B (zh) | 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑 | |
| EP3922251B1 (en) | Cancer immunotheraphy adjuvant | |
| Marabelle et al. | Radiotherapy and toll-like receptor agonists | |
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies | |
| US20190365719A1 (en) | Combination treatments of hsp90 inhibitors for enhancing tumor immunogenicity and methods of use thereof | |
| WO2019076269A1 (zh) | 甲羟戊酸通路抑制剂及其药物组合物 | |
| JP2020531495A5 (cg-RX-API-DMAC7.html) | ||
| EP3630126A1 (en) | Ceramide nanoliposomes, compositions and methods of using for immunotherapy | |
| CN110891944A (zh) | 用于治疗癌症的化合物、组合物及其用途 | |
| Cornel et al. | P09. 02 Epigenetic modulation of neuroblastoma enhances T-and NK cell immunogenicity via induction of surface expression of MHC class I and MICA/MICB | |
| Wang et al. | Combined use of TLR4 and TLR7/8 agonists to improve the efficacy of immune checkpoint inhibitors in “hot” tumor treatment and the establishment of long-term immune protection | |
| Vankayalapati et al. | 870 Targeting GCN2 kinase-driven stress response inactivation to restore tumor immunity in metastatic triple negative breast cancer | |
| RU2021106915A (ru) | Комбинированная терапия злокачественной опухоли с использованием производного хинолинкарбоксамида | |
| Hwu et al. | Effective Innate and Adaptive Antimelanoma | |
| HK1250213B (en) | Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide | |
| HK1248546B (en) | Combination use of wt1 antigen peptide and immunomodulator |